Q: A BNN guest recently made mention of a European competitor that may soon enter the NA marketplace that could severely impact Savaria's business, to the point where a friend of his considers SIS a short (I think this is also in part due to its valuation). Are you aware of any such threat on the horizon? Does Savaria have any kind of moat or special advantage that might insulate it from new (presumably established & high quality) competition?
You can view 3 more answers this month. Sign up for a free trial for unlimited access.
Investment Q&A
Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.
Q: Did you glean anything from the company call?
Q: Do you think a buy-out or partnership is likely in the cards for PLI? Would GUD have any interest?
Q: Would this company have technology that would make it attractive to US firms as a take out, it seems to be competing against companies that have market caps in the billions in the US, in this same field.
Thanks
Thanks
Q: I am sure you're getting a lot of questions regarding PLI
Is there any hope recovering our capital?
Is there any hope recovering our capital?
Q: Any comment on the news release after closing last night?
Q: Your thought on RHT at current price?
Q: Hello 5
I am up $886 with ABBV. Time to sell given the problems or stick with it for about 10 year outlook for the dividend?
thanx
Stanley
I am up $886 with ABBV. Time to sell given the problems or stick with it for about 10 year outlook for the dividend?
thanx
Stanley
Q: Good Morning!
Abbvie is in free fall. What’s up?
Abbvie is in free fall. What’s up?
Q: Why is this crashing?
Q: Hi Team,
Your thought on COV, since they drop some 30% form the high. Is it worth to add on more or let it go and move on.
Thank you and appreciate as always.
Tak
Your thought on COV, since they drop some 30% form the high. Is it worth to add on more or let it go and move on.
Thank you and appreciate as always.
Tak
Q: Good morning 5i
While skimming local media this morning the article in globe business caught my attention; Acasta.
Taking the article at face value highlights the benefit of not being rushed to put capital to use. Mistakes can be costly; overpaying and large debt levels.
I don't like seeing Gud underwater but I know it is not permanently impaired nor priced for destruction.
Pg b17. Globe business. Mar. 24
Thanks for the service.
Dave
While skimming local media this morning the article in globe business caught my attention; Acasta.
Taking the article at face value highlights the benefit of not being rushed to put capital to use. Mistakes can be costly; overpaying and large debt levels.
I don't like seeing Gud underwater but I know it is not permanently impaired nor priced for destruction.
Pg b17. Globe business. Mar. 24
Thanks for the service.
Dave
Q: I would appreciate your views upon RX as a holding for potential growth within a TFSA. Thank you.
Q: Hi
Can I have your review of their results just released and whether it's worth staying with this company or moving on to another in the space. If moving, what company would you recomend? Thanks
Can I have your review of their results just released and whether it's worth staying with this company or moving on to another in the space. If moving, what company would you recomend? Thanks
Q: Hello team,
Would you buy ATE today or would you wait? Is there a good upside from here or the easy money is already made and there would be a period of consolidation?
Thanks!
Would you buy ATE today or would you wait? Is there a good upside from here or the easy money is already made and there would be a period of consolidation?
Thanks!
Q: Obviously there is a lot of interests after the result. Should we take this with a grain of salt? Is this still a risky investment or you see brighter future from here on.
Thanks
Thanks
Q: Mr. Hodson, still no news about GUD spending its hoard of cash ? How long can they do this ? At some point, they will spend the money...No use not using it !
Q: Can you please comment on the acquisition made today? After lots of acquisitions should this not finally alleviate growth concerns?
Also, from Cardiome's recent investor presentation it looks like they had Canadian tax credits of 190M cad @ 26% = $49M (versus the company's 75M total tax credits). I am assuming that is what "NOL CFWDs" means? From the news release it appears Cipher may get these credits in the transaction. That seems very beneficial for Cipher as they would be in a position to actually use them immediately where Cardiome operating at a loss could not. Is my thinking correct here?
Thanks!
Also, from Cardiome's recent investor presentation it looks like they had Canadian tax credits of 190M cad @ 26% = $49M (versus the company's 75M total tax credits). I am assuming that is what "NOL CFWDs" means? From the news release it appears Cipher may get these credits in the transaction. That seems very beneficial for Cipher as they would be in a position to actually use them immediately where Cardiome operating at a loss could not. Is my thinking correct here?
Thanks!
Q: a followup to the results announced by Antibe, Knight (gud/t) has been given a spot of the Board of Directors. How significant is this news and what relationship does Knight have with Antibe,ie: have they previously participated in finance for shares,etc. I thought Knight would move on this news but in the red today. Thanks as usual, JB from beautiful Laurentian Mountains. PS:great spring skiing here
-
Amgen Inc. (AMGN)
-
Biogen Inc. (BIIB)
-
Becton Dickinson and Company (BDX)
-
Edwards Lifesciences Corporation (EW)
-
Johnson & Johnson (JNJ)
Q: Could you please rank these USA healthcare stocks in terms of long term capital appreciation. No immediate need for income, looking more for growth. Besides these names, do you see any other interesting healthcare names in the USA with good long term growth prospects? Thanks as always